Bristol-Myers Squibb Release: Opdivo (nivolumab) First PD-1 Inhibitor To Demonstrate Superior Overall Survival Versus Standard Of Care (docetaxel) In Previously-Treated Non-Squamous Non-Small Cell Lung Cancer In Pivotal Phase III Trial

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today announced that Opdivo (nivolumab) is the first PD-1 inhibitor to demonstrate superior overall survival versus standard of care (docetaxel) in an open-label, randomized Phase III study (CheckMate -057) evaluating previously-treated patients with advanced, non-squamous non-small cell lung cancer (NSCLC). A 27% reduction in the risk of progression or death – the primary study endpoint – was reported for Opdivo (n=292) versus docetaxel (n=290) based upon a hazard ratio of 0.73 (96% CI, 0.59-0.89; P = 0.0015).

Help employers find you! Check out all the jobs and post your resume.